Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Dyslipidemia-Pipeline Review, H1 2015

Dyslipidemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Dyslipidemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Dyslipidemia-Pipeline Review, H1 2015', provides an overview of the Dyslipidemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Dyslipidemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Dyslipidemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Dyslipidemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Dyslipidemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Dyslipidemia Overview 9

Therapeutics Development 10

Pipeline Products for Dyslipidemia-Overview 10

Pipeline Products for Dyslipidemia-Comparative Analysis 11

Dyslipidemia-Therapeutics under Development by Companies 12

Dyslipidemia-Therapeutics under Investigation by Universities/Institutes 16

Dyslipidemia-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Dyslipidemia-Products under Development by Companies 20

Dyslipidemia-Products under Investigation by Universities/Institutes 24

Dyslipidemia-Companies Involved in Therapeutics Development 25

Amgen Inc. 25

Arisaph Pharmaceuticals, Inc. 26

AstraZeneca PLC 27

Biocon Limited 28

Cadila Pharmaceuticals Ltd. 29

Cerenis Therapeutics Holding SA 30

Chong Kun Dang Pharmaceutical Corp. 31

CymaBay Therapeutics, Inc. 32

Daiichi Sankyo Company, Limited 33

Debiopharm International S.A. 34

Dezima Pharma BV 35

Dr. Reddy's Laboratories Limited 36

Genfit SA 37

GlaxoSmithKline plc 38

Hanmi Pharmaceuticals, Co. Ltd. 39

High Point Pharmaceuticals, LLC 40

Intas Pharmaceuticals Ltd. 41

Jenrin Discovery, Inc. 42

JW Pharmaceutical Corporation 43

Kissei Pharmaceutical Co., Ltd. 44

Kotobuki Pharmaceutical Co., Ltd. 45

Kowa Company, Ltd. 46

Kymab Limited 47

Lipicard Technologies Limited 48

Merck & Co., Inc. 49

Nippon Chemiphar Co., Ltd. 50

Novartis AG 51

Pfizer Inc. 52

Pharmena SA 53

Piramal Enterprises Limited 54

Reviva Pharmaceuticals Inc. 55

Sanofi 56

Takeda Pharmaceutical Company Limited 57

Torrent Pharmaceuticals Limited 58

Zydus Cadila Healthcare Limited 59

Dyslipidemia-Therapeutics Assessment 60

Assessment by Monotherapy Products 60

Assessment by Combination Products 61

Assessment by Target 62

Assessment by Mechanism of Action 64

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

(ezetimibe + rosuvastatin calcium)-Drug Profile 70

(niacin + aspirin)-Drug Profile 71

(pitavastatin + valsartan)-Drug Profile 72

(rosuvastatin calcium + ezetimibe)-Drug Profile 73

(statin + niacin + aspirin)-Drug Profile 74

4655-K09-Drug Profile 75

anacetrapib-Drug Profile 76

ARI-3037MO-Drug Profile 78

AZ-12260493-Drug Profile 80

BioE-1115-Drug Profile 81

bococizumab-Drug Profile 82

BSN-852-Drug Profile 83

C-24-Drug Profile 84

C-3-Drug Profile 85

Centatin-Drug Profile 86

CKD-519-Drug Profile 87

Debio-0930B-Drug Profile 88

DEZ-001-Drug Profile 89

DF-461-Drug Profile 90

DGAT-1-Drug Profile 91

DRL-17822-Drug Profile 92

evolocumab-Drug Profile 93

GFT-505-Drug Profile 96

GSK-2041706-Drug Profile 99

HCP-1105-Drug Profile 100

HCP-1305-Drug Profile 101

HDL Receptor Enhancer-Drug Profile 102

HPP-593-Drug Profile 103

INSUPR-001-Drug Profile 104

JD-5037-Drug Profile 105

K-312-Drug Profile 106

K-877-Drug Profile 107

KT6-971-Drug Profile 108

KTA-439-Drug Profile 109

KY-1020-Drug Profile 110

LP-071-Drug Profile 111

LT-5421-Drug Profile 112

LT-5423-Drug Profile 113

MAT-9001-Drug Profile 114

MBX-8025-Drug Profile 115

MGL-3196-Drug Profile 117

NC-2400-Drug Profile 119

ND-630-Drug Profile 120

ND-654-Drug Profile 121

P-7435-Drug Profile 122

Peroxibrate-Drug Profile 123

pitavastatin CR-Drug Profile 124

Recombinant ApoE4 for Dyslipidemia-Drug Profile 125

RP-17000-Drug Profile 126

Small Molecule 1 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity, Dyslipidemia and Type 2 Diabetes-Drug Profile 127

Small Molecule 2 to Inhibit Diacylglycerol Acyltransferase Inhibitor for Obesity Dyslipidemia and Type 2 Diabetes-Drug Profile 128

Small Molecule to Activate Lipoprotein Lipase for Dyslipidemia-Drug Profile 129

Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia-Drug Profile 130

Small Molecules for Dyslipidemia and Hypertriglyceridemia-Drug Profile 131

Small Molecules to Inhibit DGAT-1 for Dyslipidemia and Obesity-Drug Profile 132

Small Molecules to Inhibit DGAT-1 for Metabolic Disorders-Drug Profile 133

Small Molecules to Inhibit Endothelial Lipase for Dyslipidemia-Drug Profile 134

SPX-100-Drug Profile 135

SPX-8522876-Drug Profile 136

Synthetic Peptides for Dyslipidemic and Vascular Disorders-Drug Profile 137

TAP-311-Drug Profile 138

TRC-210258-Drug Profile 139

TRIA-662-Drug Profile 140

VK-0214-Drug Profile 142

ZLN-005-Drug Profile 143

ZLN-024-Drug Profile 144

ZYH-7-Drug Profile 145

ZYT-1-Drug Profile 146

Dyslipidemia-Recent Pipeline Updates 147

Dyslipidemia-Dormant Projects 168

Dyslipidemia-Discontinued Products 175

Dyslipidemia-Product Development Milestones 180

Featured News & Press Releases 180

Appendix 194

Methodology 194

Coverage 194

Secondary Research 194

Primary Research 194

Expert Panel Validation 194

Contact Us 195

Disclaimer 195

List of Tables

Number of Products under Development for Dyslipidemia, H1 2015 15

Number of Products under Development for Dyslipidemia-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Dyslipidemia-Pipeline by Amgen Inc., H1 2015 30

Dyslipidemia-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 31

Dyslipidemia-Pipeline by AstraZeneca PLC, H1 2015 32

Dyslipidemia-Pipeline by Biocon Limited, H1 2015 33

Dyslipidemia-Pipeline by Cadila Pharmaceuticals Ltd., H1 2015 34

Dyslipidemia-Pipeline by Cerenis Therapeutics Holding SA, H1 2015 35

Dyslipidemia-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 36

Dyslipidemia-Pipeline by CymaBay Therapeutics, Inc., H1 2015 37

Dyslipidemia-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 38

Dyslipidemia-Pipeline by Debiopharm International S.A., H1 2015 39

Dyslipidemia-Pipeline by Dezima Pharma BV , H1 2015 40

Dyslipidemia-Pipeline by Dr. Reddy's Laboratories Limited, H1 2015 41

Dyslipidemia-Pipeline by Genfit SA, H1 2015 42

Dyslipidemia-Pipeline by GlaxoSmithKline plc, H1 2015 43

Dyslipidemia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 44

Dyslipidemia-Pipeline by High Point Pharmaceuticals, LLC, H1 2015 45

Dyslipidemia-Pipeline by Intas Pharmaceuticals Ltd., H1 2015 46

Dyslipidemia-Pipeline by Jenrin Discovery, Inc., H1 2015 47

Dyslipidemia-Pipeline by JW Pharmaceutical Corporation, H1 2015 48

Dyslipidemia-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 49

Dyslipidemia-Pipeline by Kotobuki Pharmaceutical Co., Ltd., H1 2015 50

Dyslipidemia-Pipeline by Kowa Company, Ltd., H1 2015 51

Dyslipidemia-Pipeline by Kymab Limited, H1 2015 52

Dyslipidemia-Pipeline by Lipicard Technologies Limited, H1 2015 53

Dyslipidemia-Pipeline by Merck & Co., Inc., H1 2015 54

Dyslipidemia-Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 55

Dyslipidemia-Pipeline by Novartis AG, H1 2015 56

Dyslipidemia-Pipeline by Pfizer Inc., H1 2015 57

Dyslipidemia-Pipeline by Pharmena SA, H1 2015 58

Dyslipidemia-Pipeline by Piramal Enterprises Limited, H1 2015 59

Dyslipidemia-Pipeline by Reviva Pharmaceuticals Inc., H1 2015 60

Dyslipidemia-Pipeline by Sanofi, H1 2015 61

Dyslipidemia-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 62

Dyslipidemia-Pipeline by Torrent Pharmaceuticals Limited, H1 2015 63

Dyslipidemia-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 64

Assessment by Monotherapy Products, H1 2015 65

Assessment by Combination Products, H1 2015 66

Number of Products by Stage and Target, H1 2015 68

Number of Products by Stage and Mechanism of Action, H1 2015 70

Number of Products by Stage and Route of Administration, H1 2015 72

Number of Products by Stage and Molecule Type, H1 2015 74

Dyslipidemia Therapeutics-Recent Pipeline Updates, H1 2015 152

Dyslipidemia-Dormant Projects, H1 2015 173

Dyslipidemia-Dormant Projects (Contd..1), H1 2015 174

Dyslipidemia-Dormant Projects (Contd..2), H1 2015 175

Dyslipidemia-Dormant Projects (Contd..3), H1 2015 176

Dyslipidemia-Dormant Projects (Contd..4), H1 2015 177

Dyslipidemia-Dormant Projects (Contd..5), H1 2015 178

Dyslipidemia-Dormant Projects (Contd..6), H1 2015 179

Dyslipidemia-Discontinued Products, H1 2015 180

Dyslipidemia-Discontinued Products (Contd..1), H1 2015 181

Dyslipidemia-Discontinued Products (Contd..2), H1 2015 182

Dyslipidemia-Discontinued Products (Contd..3), H1 2015 183

Dyslipidemia-Discontinued Products (Contd..4), H1 2015 184

List of Figures

Number of Products under Development for Dyslipidemia, H1 2015 15

Number of Products under Development for Dyslipidemia-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 65

Assessment by Combination Products, H1 2015 66

Number of Products by Top 10 Targets, H1 2015 67

Number of Products by Stage and Top 10 Targets, H1 2015 67

Number of Products by Top 10 Mechanism of Actions, H1 2015 69

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 69

Number of Products by Top 10 Routes of Administration, H1 2015 71

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 72

Number of Products by Top 10 Molecule Types, H1 2015 73

Number of Products by Stage and Top 10 Molecule Types, H1 2015 74

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Arisaph Pharmaceuticals, Inc.

AstraZeneca PLC

Biocon Limited

Cadila Pharmaceuticals Ltd.

Cerenis Therapeutics Holding SA

Chong Kun Dang Pharmaceutical Corp.

CymaBay Therapeutics, Inc.

Daiichi Sankyo Company, Limited

Debiopharm International S.A.

Dezima Pharma BV

Dr. Reddy's Laboratories Limited

Genfit SA

GlaxoSmithKline plc

Hanmi Pharmaceuticals, Co. Ltd.

High Point Pharmaceuticals, LLC

Intas Pharmaceuticals Ltd.

Jenrin Discovery, Inc.

JW Pharmaceutical Corporation

Kissei Pharmaceutical Co., Ltd.

Kotobuki Pharmaceutical Co., Ltd.

Kowa Company, Ltd.

Kymab Limited

Lipicard Technologies Limited

Merck & Co., Inc.

Nippon Chemiphar Co., Ltd.

Novartis AG

Pfizer Inc.

Pharmena SA

Piramal Enterprises Limited

Reviva Pharmaceuticals Inc.

Sanofi

Takeda Pharmaceutical Company Limited

Torrent Pharmaceuticals Limited

Zydus Cadila Healthcare Limited

Dyslipidemia Therapeutic Products under Development, Key Players in Dyslipidemia Therapeutics, Dyslipidemia Pipeline Overview, Dyslipidemia Pipeline, Dyslipidemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com